Open AccessManagement of patients with chronic obstructive pulmonary disease in COVID-19 pandemic
Author(s) -
S. I. Krayushkin,
Irina Vyacheslavovna Ivakhnenko,
Е. А. Сущук,
A. V. Zaporoshchenko
Publication year - 2020
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2020-19-77-80
Subject(s) - pandemic , copd , medicine , covid-19 , coronavirus , pulmonary disease , disease , intensive care medicine , adverse effect , infectious disease (medical specialty) , virology , outbreak
The pandemic of COVID-19, a disease caused by a novelcoronavirus SARS-CoV-2, is associated with significant morbidityand mortality. Recent data showed that patients with chronicobstructive pulmonary disease (COPD) have an increased riskfor severity and complicated COVID-19 infection. In coronavirus pandemic, patients with COPD should continue standardmaintenance therapy, including bronchodilators and their combination with inhaled glucocorticosteroids, in order to maintain astable condition and prevent the development of exacerbationsthat can be provoked by COVID-19. It is important for this groupof patients to carefully monitor the condition and follow measures aimed at preventing infection with coronavirus infectiondue to the increased risk of adverse outcomes.